Eastern Cooperative Oncology Group Clinical Trials

东部肿瘤合作组临床试验

基本信息

  • 批准号:
    7426349
  • 负责人:
  • 金额:
    $ 45.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1978
  • 资助国家:
    美国
  • 起止时间:
    1978-06-01 至 2010-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Since 1973, Northwestern University has been a funded member of the Eastern Cooperative Oncology Group (ECOG). Through the years, the University has consistently offered its resources and investigator commitment to both the scientific development of ECOG and to the accrual of patients to ECOG clinical trials and ancillary studies. Northwestern's Robert H. Lurie Comprehensive Cancer Center provides the essential structural support for the University's ECOG program including its affiliated institutions (Cooperative Group Outreach Program [CGOP]). The Cancer Center successfully maintained its NCI Core Grant funding in 1996 (CA 60553) and in 1997 was named an NCI Comprehensive Cancer Center. Furthermore, the Cancer Center has continued to integrate its clinical and laboratory science programs into a well-defined structure which provides important shared resources for Cancer Center members to support ECOG activity (e.g., Clinical Research Office, Serum and Tissue Banks, hematopathology, etc.) AI B. Benson III M.D., F.A.C.P. continues his role as Principal Investigator and Leo I. Gordon, M.D. continues as the Co-Principal Investigator for Northwestern's ECOG grant. Both physicians maintain leadership roles within the Cancer Center resulting in enhanced integration of ECOG and Cancer Center activity. Northwestern's commitment to ECOG is exemplified by its consistent entry of new patients to ECOG trials with a substantial number of cases in follow-up each year. In addition, Northwestern investigators continue to chair numerous ECOG clinical trials and hold a number of key leadership positions within ECOG which include: GI Committee chair (Benson), Data Monitoring Committee chair (Benson), elected Nominating Committee member (Benson), Leukemia Committee chair (Tallman), Laboratory Science Committee chair (Rosen), Oncology Nursing Committee chair (Stucky-Marshall), Lymphoma Committee co-chair (Gordon), Surgery Committee co-chair (Talamonti). In 2001, the Pathology Coordinating Office-Reference Laboraotory (PCO-RL) was relocated to Northwestern's Cancer Center. Since 1998, Northwestern investigators have authored or co-authored 79 publications and 84 abstracts and accrued 1403 patients with 1424 patients in follow-up.
描述(由申请人提供):自1973年以来,西北大学一直是东部合作肿瘤学集团(ECOG)的资助成员。 多年来,该大学一直对ECOG的科学发展以及患者对ECOG临床试验和辅助研究的应计提出的资源和研究者的承诺。 西北的罗伯特·H·卢里综合癌症中心为大学的ECOG计划提供了基本的结构支持,包括其附属机构(合作集团外展计划[CGOP])。 癌症中心在1996年(CA 60553)成功维持其NCI核心赠款资金,并于1997年被任命为NCI综合癌症中心。 此外,癌症中心继续将其临床和实验室科学计划整合到一个定义明确的结构中,为癌症中心成员提供了重要的共享资源,以支持ECOG活动(例如,临床研究办公室,血清和组织库,血清病理学等)AI B. Benson III M.D.,F.A.C.P.继续担任首席研究员的角色和M.D. Leo I. Gordon继续担任西北ECOG Grant的联合主持调查员。 两位医生都在癌症中心保持领导作用,从而增强了ECOG和癌症中心活动的整合。西北航空对ECOG的承诺得到了新的患者的一致进入ECOG试验的体现,每年随访中有大量案件。 In addition, Northwestern investigators continue to chair numerous ECOG clinical trials and hold a number of key leadership positions within ECOG which include: GI Committee chair (Benson), Data Monitoring Committee chair (Benson), elected Nominating Committee member (Benson), Leukemia Committee chair (Tallman), Laboratory Science Committee chair (Rosen), Oncology Nursing Committee chair (Stucky-Marshall), Lymphoma Committee co-chair (戈登),手术委员会联席主席(Talamonti)。 2001年,病理协调办公室参考劳动力(PCO-RL)被搬迁到西北的癌症中心。自1998年以来,西北调查人员撰写或共同撰写了79个出版物和84次摘要,并累积了1403名患者,有1424名患者的随访。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AL B BENSON其他文献

AL B BENSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AL B BENSON', 18)}}的其他基金

Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making
真实世界数据在监管决策中生成真实世界证据
  • 批准号:
    10797946
  • 财政年份:
    2023
  • 资助金额:
    $ 45.24万
  • 项目类别:
Northwestern University Lead Academic Participating Site, GY4 Supplemental Request
西北大学主导学术参与网站,GY4 补充请求
  • 批准号:
    10736415
  • 财政年份:
    2022
  • 资助金额:
    $ 45.24万
  • 项目类别:
Northwestern University Lead Academic Participating Site
西北大学主导学术参与网站
  • 批准号:
    10357915
  • 财政年份:
    2019
  • 资助金额:
    $ 45.24万
  • 项目类别:
Northwestern University Lead Academic Participating Site
西北大学主导学术参与网站
  • 批准号:
    10583453
  • 财政年份:
    2019
  • 资助金额:
    $ 45.24万
  • 项目类别:
Northwestern University Lead Academic Participating Site
西北大学主导学术参与网站
  • 批准号:
    9901493
  • 财政年份:
    2019
  • 资助金额:
    $ 45.24万
  • 项目类别:
Northwestern University Lead Academic Participating Site Supplement Year 2
西北大学主导学术参与网站补充第二年
  • 批准号:
    10299729
  • 财政年份:
    2019
  • 资助金额:
    $ 45.24万
  • 项目类别:
Northwestern University Lead Academic Participating Site
西北大学主导学术参与网站
  • 批准号:
    10062109
  • 财政年份:
    2019
  • 资助金额:
    $ 45.24万
  • 项目类别:
NU 98X3: IRINOTECAN (CPT-11) AND GEMCITABINE IN PATIENTS WITH SOLID TUMORS
NU 98X3:伊立替康 (CPT-11) 和吉西他滨治疗实体瘤患者
  • 批准号:
    7604237
  • 财政年份:
    2006
  • 资助金额:
    $ 45.24万
  • 项目类别:
NU 98X3: IRINOTECAN (CPT-11) AND GEMCITABINE IN PATIENTS WITH SOLID TUMORS
NU 98X3:伊立替康 (CPT-11) 和吉西他滨治疗实体瘤患者
  • 批准号:
    7200422
  • 财政年份:
    2004
  • 资助金额:
    $ 45.24万
  • 项目类别:
NU 98X3: Irinotecan (CPT-11) and Gemcitabine in Patients with Solid Tumors
NU 98X3:伊立替康 (CPT-11) 和吉西他滨治疗实体瘤患者
  • 批准号:
    7040344
  • 财政年份:
    2003
  • 资助金额:
    $ 45.24万
  • 项目类别:

相似国自然基金

以家庭为中心的癌症患儿多症状管理模式的构建及干预:基于症状管理理论的实证研究
  • 批准号:
    71704106
  • 批准年份:
    2017
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Northwestern University Lead Academic Participating Site
西北大学主导学术参与网站
  • 批准号:
    10357915
  • 财政年份:
    2019
  • 资助金额:
    $ 45.24万
  • 项目类别:
Northwestern University Lead Academic Participating Site
西北大学主导学术参与网站
  • 批准号:
    10583453
  • 财政年份:
    2019
  • 资助金额:
    $ 45.24万
  • 项目类别:
Northwestern University Lead Academic Participating Site
西北大学主导学术参与网站
  • 批准号:
    9901493
  • 财政年份:
    2019
  • 资助金额:
    $ 45.24万
  • 项目类别:
Northwestern University Lead Academic Participating Site
西北大学主导学术参与网站
  • 批准号:
    10062109
  • 财政年份:
    2019
  • 资助金额:
    $ 45.24万
  • 项目类别:
Clinical Research Office
临床研究办公室
  • 批准号:
    7698897
  • 财政年份:
    2008
  • 资助金额:
    $ 45.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了